Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 1;152(9):1977-1988.
doi: 10.1002/ijc.34406. Epub 2023 Jan 17.

The WID-EC test for the detection and risk prediction of endometrial cancer

James E Barrett  1   2   3 , Allison Jones  2 , Iona Evans  2 , Chiara Herzog  1 , Daniel Reisel  2 , Adeola Olaitan  2 , Tim Mould  2 , Nicola MacDonald  2 , Konstantinos Doufekas  2 , Claire Newton  4   5 , Emma J Crosbie  6   7 , Line Bjørge  8   9 , Nicoletta Colombo  10   11 , Lukas Dostalek  12   13 , Laura Costas  14 , Paula Peremiquel-Trillas  14 , Jordi Ponce  15 , Xavier Matias-Guiu  16 , Michal Zikan  12   13 , David Cibula  13 , Jiangrong Wang  17 , Karin Sundström  17 , Joakim Dillner  17 , Martin Widschwendter  1   2   3
Affiliations
Free article

The WID-EC test for the detection and risk prediction of endometrial cancer

James E Barrett et al. Int J Cancer. .
Free article

Abstract

The incidence of endometrial cancer is rising. Measures to identify women at risk and to detect endometrial cancer earlier are required to reduce the morbidity triggered by the aggressive treatment required for advanced endometrial cancer. We developed the WID-EC (Women's cancer risk IDentification-Endometrial Cancer) test, which is based on DNA methylation at 500 CpG sites, in a discovery set of cervical liquid-based cytology samples from 1086 women with and without an endometrial cancer (217 cancer cases and 869 healthy controls) with a worse prognosis (grade 3 or ≥stage IB). We validated the WID-EC test in an independent external validation set of 64 endometrial cancer cases and 225 controls. We further validated the test in 150 healthy women (prospective set) who provided a cervical sample as part of the routine Swedish cervical screening programme, 54 of whom developed endometrial cancer within 3 years of sample collection. The WID-EC test identified women with endometrial cancer with a receiver operator characteristic area under the curve (AUC) of 0.92 (95% CI: 0.88-0.97) in the external set and of 0.82 (95% CI: 0.74-0.89) in the prospective validation set. Using an optimal cutoff, cancer cases were detected with a sensitivity of 86% and a specificity of 90% in the external validation set, and a sensitivity and specificity of 52% and 98% respectively in the prospective validation set. The WID-EC test can identify women with or at risk of endometrial cancer.

Keywords: DNA methylation; cervical sample; endometrial cancer; epigenetics; risk prediction.

PubMed Disclaimer

References

REFERENCES

    1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913-2921.
    1. de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20(9):1273-1285.
    1. Wan YL, Beverley-Stevenson R, Carlisle D, et al. Working together to shape the endometrial cancer research agenda: the top ten unanswered research questions. Gynecol Oncol. 2016;143(2):287-293.
    1. Badrick E, Cresswell K, Ellis P, Detecting Cancer Early Priority Setting Partnership Steering Group, Renehan AG, Crosbie EJ. Top ten research priorities for detecting cancer early. Lancet Public Health. 2019;4(11):e551.
    1. Jacobs I, Gentry-Maharaj A, Burnell M, et al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol. 2011;12(1):38-48.

Publication types